ARTICLE | Product Development
Two-dose schedule, infection levels may shift timelines for AZ-Oxford vaccine
Readouts from AZ-Oxford, BioNTech-Pfizer, CanSino raise expectations for virus-specific T cell responses
July 21, 2020 1:15 AM UTC
AstraZeneca and Oxford will likely move forward with a two-dose schedule for their adenoviral vaccine following an anticipated Phase I/II readout, a decision that could shift timelines, availability and tolerability of one of the COVID-19 vaccine front-runners.
Data from the University of Oxford’s Phase I/II trial of AZD1222 (formerly ChAdOx1 nCoV-19) showed the vaccine triggered both neutralizing antibodies and T cell responses against the virus’ spike protein when given as a one- or two-dose regimen, but a higher percentage of volunteers had antibody responses in the two-dose cohort...